Artal Group »

Tourmaline Bio shares owned by Artal Group

Quarter-by-quarter ownership of Tourmaline Bio (TRML) shares owned by Artal Group from 13F filings

Historical chart of Artal Group investment in Tourmaline Bio

Tip: Access up to 7 years of quarterly data

All positions including Tourmaline Bio held by Artal Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Tourmaline Bio by Artal Group

Quarter filed Position value Share count Share price at filing
2023-12-31 $2.4M 91k 26.19

More positions owned by Artal Group

Cava Group Ord (CAVA)
Scholar Rock Hldg Corp (SRRK)
Lexicon Pharmaceuticals Com New (LXRX)
Cytokinetics Com New (CYTK)
Apellis Pharmaceuticals (APLS)
Beigene Sponsored Adr (BGNE)
Kymera Therapeutics (KYMR)
Amicus Therapeutics (FOLD)
Morphic Hldg (MORF)
Springworks Therapeutics (SWTX)
Silence Therapeutics Ads (SLN)
Revolution Medicines (RVMD)
Argenx Se Sponsored Adr (ARGX)
Neumora Therapeutics (NMRA)
Arrowhead Pharmaceuticals (ARWR)

View all positions for Artal Group

Top funds holding Tourmaline Bio

Blue Owl Capital Holdings
QVT Financial
Braidwell
venBio Select Advisor
Vanguard Group
Dr. Jeffrey R. Jay, M.D.
Qiming U.S. Ventures Management
Vivo Capital
Nantahala Capital Management
Balyasny Asset Management
Logos Global Management
Artal Group
AlphaCentric Advisors
Two Sigma Investments
HighTower Advisors

View all funds holding Tourmaline Bio